EvolveImmune Therapeutics, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
EvolveImmune Therapeutics, Inc. - overview
Established
2020
Location
Branford, CT, US
Primary Industry
Biotechnology
About
Based in Connecticut, US, and founded in 2020, EvolveImmune Therapeutics is a biotechnology company focused on developing precision cancer medicines to deliver superior patient outcomes compared to current anti-cancer therapies. The company was co-founded by Charles Fuchs, Sidi Chen, and Stephen Bloch (CEO). In December 2023, EvolveImmune Therapeutics, Inc. raised USD 37 million in venture funding from returning investors Pfizer Venture Investments, Solasta Ventures, and Takeda Ventures, with participation from investor Bristol-Myers Squibb.
The company's main service is the creation of therapeutic solutions for cancer, and its primary market is the oncology sector of the healthcare industry. EvolveImmune Therapeutics is developing first-in-category, multifunctional biotherapeutics designed to overcome cancer-driven immunodeficiency in a range of solid tumors and hematological cancers. The company plans to use December 2023 funding to advance its groundbreaking biotherapeutic EVOLVE platform and conduct first-in-human clinical trials in 2024.
Current Investors
Pfizer Venture Investments, Takeda Ventures, Bristol-Myers Squibb
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy
Website
www.evolveimmune.com
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.